CA2408622A1 - Methods for inhibiting proliferation and inducing apoptosis in cancer cells - Google Patents

Methods for inhibiting proliferation and inducing apoptosis in cancer cells Download PDF

Info

Publication number
CA2408622A1
CA2408622A1 CA002408622A CA2408622A CA2408622A1 CA 2408622 A1 CA2408622 A1 CA 2408622A1 CA 002408622 A CA002408622 A CA 002408622A CA 2408622 A CA2408622 A CA 2408622A CA 2408622 A1 CA2408622 A1 CA 2408622A1
Authority
CA
Canada
Prior art keywords
leukotriene
alkyl
compound
cancer cells
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002408622A
Other languages
English (en)
French (fr)
Inventor
Thomas E. Adrian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creighton University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2408622A1 publication Critical patent/CA2408622A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002408622A 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells Abandoned CA2408622A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21934400P 2000-05-09 2000-05-09
US60/219,344 2000-05-09
PCT/US2001/040697 WO2001085166A1 (en) 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Publications (1)

Publication Number Publication Date
CA2408622A1 true CA2408622A1 (en) 2001-11-15

Family

ID=22818912

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002408622A Abandoned CA2408622A1 (en) 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Country Status (11)

Country Link
EP (1) EP1326605A4 (zh)
JP (1) JP2003532675A (zh)
KR (1) KR20030019372A (zh)
CN (1) CN1237968C (zh)
AU (1) AU2001261832A1 (zh)
BR (1) BR0110473A (zh)
CA (1) CA2408622A1 (zh)
MX (1) MXPA02010974A (zh)
NO (1) NO20025343L (zh)
NZ (1) NZ522387A (zh)
WO (1) WO2001085166A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
EP2034022A1 (en) 2007-09-10 2009-03-11 Universite Libre De Bruxelles Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
EA023067B1 (ru) 2012-01-10 2016-04-29 Эли Лилли Энд Компани Соединение, представляющее собой антагонист лейкотриена b
RU2667644C2 (ru) 2013-04-22 2018-09-21 Тотиги Инститьют Оф Клиникал Патолоджи Противоопухолевое средство
BR112016011170B1 (pt) 2013-12-20 2023-01-10 Novartis Ag Derivados de ácido heteroaril butanóico, seus usos, combinação e composição farmacêutica

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
WO1996006604A2 (en) * 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
HUP9904672A2 (hu) * 1997-03-21 2000-05-28 Eli Lilly And Co. Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták
AU1916501A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
EA200200545A1 (ru) * 1999-11-11 2002-12-26 Эли Лилли Энд Компани Онколитические комбинации для лечения рака
JP2003513914A (ja) * 1999-11-11 2003-04-15 イーライ・リリー・アンド・カンパニー 癌の処置のための腫瘍崩壊薬の組み合わせ
AU1916601A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Also Published As

Publication number Publication date
MXPA02010974A (es) 2004-09-06
CN1237968C (zh) 2006-01-25
EP1326605A4 (en) 2004-03-17
AU2001261832A1 (en) 2001-11-20
NZ522387A (en) 2003-09-26
NO20025343L (no) 2003-01-09
EP1326605A1 (en) 2003-07-16
KR20030019372A (ko) 2003-03-06
NO20025343D0 (no) 2002-11-07
JP2003532675A (ja) 2003-11-05
WO2001085166A1 (en) 2001-11-15
CN1429111A (zh) 2003-07-09
BR0110473A (pt) 2003-04-01

Similar Documents

Publication Publication Date Title
Masferrer et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
Hao et al. Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival
Kamide et al. Selective activator protein‐1 inhibitor T‐5224 prevents lymph node metastasis in an oral cancer model
Orita et al. Selective inhibition of fatty acid synthase for lung cancer treatment
Stuckler et al. RLIP76 Transports Vinorelbine and Mediates Drug Resistance in Non–Small Cell Lung Cancer
US10420814B2 (en) Composition for treating cancer stem cells
RU2389507C2 (ru) Лечение рака
US11046647B2 (en) Activators of the unfolded protein response
KR102361078B1 (ko) 말산-아스파르트산 왕복수송 억제제 및 카르니틴 아실카르니틴 운반자 수송 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
JP2003513920A (ja) 細胞内マロニルＣｏＡレベルの増加による癌の治療
Song et al. Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro
JP4667873B2 (ja) α５β１およびその細胞生存経路を調節する能力
CA2408622A1 (en) Methods for inhibiting proliferation and inducing apoptosis in cancer cells
Liu et al. Limonin stabilises sirtuin 6 (SIRT6) by activating ubiquitin specific peptidase 10 (USP10) in cardiac hypertrophy
Tada et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma
US20040053962A1 (en) Methods for inhibiting proliferation and inducing apoptosis in cancer cells
McGuckin et al. MUC13 Cell Surface Mucin Limits Salmonella Typhimurium Infection by Protecting the Mucosal Epithelial Barrier
US9895363B2 (en) Methods for modulating function of proliferating cell nuclear antigen (PCNA) and treating cancer with PCNA-targeting compounds
Cellai et al. Specific PAF antagonist WEB‐2086 induces terminal differentiation of murine and human leukemia cells
Jiang et al. Cinnamamide, an antitumor agent with low cytotoxicity acting on matrix metalloproteinase
WO2017103625A1 (en) Cancer treatment
Kamei et al. Ketoprofen in topical formulation decreases the matrix metalloproteinase‐2 expression and pulmonary metastatic incidence in nude mice with osteosarcoma
Liu et al. A novel small molecular STAT3 inhibitor, 5Br-6b, induces apoptosis and inhibits migration in colorectal cancer cells
JP2021127292A (ja) Ｍｅｆ２ｄ融合型急性リンパ性白血病の治療方法及び治療剤
WO2019098288A1 (ja) 抗腫瘍剤及び配合剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead